Phio Pharmaceuticals stockholders approve 1.5 million share increase to incentive plan
At its 2026 Annual Meeting on September 28, 2026, Phio Pharmaceuticals stockholders approved an amendment that raises the shares available under its 2020 Long Term Incentive Plan by 1,500,000 to a total of 2,452,017. Stockholders also re-elected six directors and ratified Grant Thornton, LLP as the independent auditor for 2026. The larger share pool allows more shares to be issued under the plan than before.
Key points
- Plan Amendment approved; shares available under the 2020 Plan rise by 1,500,000 to 2,452,017.
- Plan proposal vote: 1,155,945 for, 194,070 against, 34,468 abstained, and 3,823,097 broker non-votes.
- All six director nominees elected, including Robert J. Bitterman, to serve until the 2027 Annual Meeting; Grant Thornton ratified with 5,087,608 votes for.
- 5,207,580 shares were present of 11,617,250 outstanding at the August 4, 2026 record date.
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 28, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.